Attached files
| file | filename |
|---|---|
| EX-99.1 - Sinobiopharma, Inc. | sino_ex99-1.htm |
| EX-99.2 - Sinobiopharma, Inc. | sino_ex99-2.htm |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 8, 2010
SINOBIOPHARMA, INC.
(Exact Name of Registrant as Specified in Charter)
|
Nevada
|
333-144910
|
26-3002371
|
|
(State or Other Jurisdiction
|
(Commission File Number)
|
(IRS Employer
|
|
of Incorporation)
|
Identification No.)
|
|
8 Zhong Tian Road,
Nantong City, Jiangsu Province, People’s Republic of China 226009
|
|
(Address of Principal Executive Offices)
|
Registrant's telephone number, including area code: (86) 51-385328336
Copies to:
Gregory Sichenzia, Esq.
Jessica Yuan, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32nd Floor
New York, New York 10006
Phone: (212) 930-9700
Fax: (212) 930-9725
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
On July 8, 2010, Sinobiopharma, Inc. (the “Company”) announced that Harbinger Research LLC has initiated analyst research coverage on the Company. A copy of the press release that discusses this matter is filed as Exhibit 99.1 to, and incorporated by reference in, this report.
On July 12, 2010, the Company announced that it launched a new corporate and investor relations website at http://www.sinobp.com. A copy of the press release that discusses this matter is filed as Exhibit 99.2 to, and incorporated by reference in, this report.
In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: July 12, 2010
|
||
|
SINOBIOPHARMA, INC.
|
||
|
By:
|
/s/ Xinjie Mu
|
|
|
Xinjie Mu
|
||
|
Chief Financial Officer
|
||
3